Alnylam Officials Tout End of Novartis Alliance as Opportunity to Focus on Pipeline
November 11, 2010
Alnylam Officials Tout End of Novartis Alliance as Opportunity to Focus on Pipeline
Included in Alnylam's pipeline is a preclinical program in hypercholesterolemia, which remains on track to yield an investigational new drug application filing next year and will incorporate a new lipid-nanoparticle delivery technology developed in collaboration with Tekmira Pharmaceuticals.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - People in the News: William Rastetter, Carlo Croce, Tyler Jacks, Phillip Sharp
April 4, 2013 / Gene Silencing News - Monsanto, Alnylam Form $29.2M Alliance to Apply RNAi to Agriculture
September 6, 2012 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - In 2011, miRNAs Move Beyond 'Scientific Curiosity' as Big Pharma Externalizes Oligo Drug Development
January 5, 2012 / Gene Silencing News